Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer

Apalutamide markedly extends overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a final analysis of data from the phase-3 SPARTAN study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news